메뉴 건너뛰기




Volumn 54, Issue 2, 2005, Pages 142-150

Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; LUCIFERASE; MEVALONIC ACID; MITHRAMYCIN; PITAVASTATIN; PLASMID DNA; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SIMVASTATIN; TRANSCRIPTION FACTOR SP1;

EID: 12944319318     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.06.018     Document Type: Article
Times cited : (43)

References (38)
  • 1
    • 0002557986 scopus 로고
    • Human serum paraoxonase/arylesterase
    • W. Kalow Pergamon New York, NY
    • B.N. La Du Human serum paraoxonase/arylesterase W. Kalow Pharmacogenetics of drug metabolism 1992 Pergamon New York, NY 51 91
    • (1992) Pharmacogenetics of Drug Metabolism , pp. 51-91
    • La Du, B.N.1
  • 2
    • 0027412483 scopus 로고
    • Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase
    • M.C. Blatter, R.W. James, and S. Messmer Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase Eur. J. Biochem. 211 1993 871 879
    • (1993) Eur. J. Biochem. , vol.211 , pp. 871-879
    • Blatter, M.C.1    James, R.W.2    Messmer, S.3
  • 3
    • 0025864611 scopus 로고
    • Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
    • M.I. Mackness, S. Arrol, and P.N. Durrington Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein FEBS Lett. 286 1991 152 154
    • (1991) FEBS Lett. , vol.286 , pp. 152-154
    • MacKness, M.I.1    Arrol, S.2    Durrington, P.N.3
  • 4
    • 0027763632 scopus 로고
    • Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
    • M.I. Mackness, S. Arrol, and C. Abbott Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase Atherosclerosis 104 1993 129 135
    • (1993) Atherosclerosis , vol.104 , pp. 129-135
    • MacKness, M.I.1    Arrol, S.2    Abbott, C.3
  • 5
    • 0032522985 scopus 로고    scopus 로고
    • Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase
    • M. Aviram, M. Rosenblat, and C.L. Bisgaier Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase J. Clin. Invest. 101 1998 1581 1590
    • (1998) J. Clin. Invest. , vol.101 , pp. 1581-1590
    • Aviram, M.1    Rosenblat, M.2    Bisgaier, C.L.3
  • 6
    • 0035574446 scopus 로고    scopus 로고
    • Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype?
    • B. Mackness, G.K. Davies, and W. Turkie Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21 2001 1451 1457
    • (2001) Arterioscler. Thromb. Vasc. Biol. , vol.21 , pp. 1451-1457
    • MacKness, B.1    Davies, G.K.2    Turkie, W.3
  • 7
    • 0032537833 scopus 로고    scopus 로고
    • Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
    • D.M. Shih, L. Gu, and Y.R. Xia Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis Nature 394 1998 284 287
    • (1998) Nature , vol.394 , pp. 284-287
    • Shih, D.M.1    Gu, L.2    Xia, Y.R.3
  • 8
    • 0037162376 scopus 로고    scopus 로고
    • Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice
    • A. Tward, Y.R. Xia, and X.P. Wang Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice Circulation 106 2002 484 490
    • (2002) Circulation , vol.106 , pp. 484-490
    • Tward, A.1    Xia, Y.R.2    Wang, X.P.3
  • 9
    • 0027396833 scopus 로고
    • The molecular basis of the human serum paraoxonase activity polymorphism
    • R. Humbert, D.A. Adler, and C.M. Disteche The molecular basis of the human serum paraoxonase activity polymorphism Nat. Genet. 3 1993 73 76
    • (1993) Nat. Genet. , vol.3 , pp. 73-76
    • Humbert, R.1    Adler, D.A.2    Disteche, C.M.3
  • 10
    • 0029118601 scopus 로고
    • Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
    • J. Ruiz, H. Blanche, and R.W. James Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes Lancet 346 1995 869 872
    • (1995) Lancet , vol.346 , pp. 869-872
    • Ruiz, J.1    Blanche, H.2    James, R.W.3
  • 11
    • 0028809494 scopus 로고
    • A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
    • M. Serrato, and A.J. Marian A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease J. Clin. Invest. 96 1995 3005 3008
    • (1995) J. Clin. Invest. , vol.96 , pp. 3005-3008
    • Serrato, M.1    Marian, A.J.2
  • 12
    • 0002198623 scopus 로고    scopus 로고
    • Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
    • M.C. Garin, R.W. James, and P. Dussoix Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes J. Clin. Invest. 99 1997 62 66
    • (1997) J. Clin. Invest. , vol.99 , pp. 62-66
    • Garin, M.C.1    James, R.W.2    Dussoix, P.3
  • 13
    • 0029788728 scopus 로고    scopus 로고
    • The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
    • M. Antikainen, S. Murtomaki, and M. Syvanne The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns J. Clin. Invest. 98 1996 883 885
    • (1996) J. Clin. Invest. , vol.98 , pp. 883-885
    • Antikainen, M.1    Murtomaki, S.2    Syvanne, M.3
  • 14
    • 0030589165 scopus 로고    scopus 로고
    • Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
    • T. Suehiro, Y. Nakauchi, and M. Yamamoto Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease Int. J. Cardiol. 57 1996 69 73
    • (1996) Int. J. Cardiol. , vol.57 , pp. 69-73
    • Suehiro, T.1    Nakauchi, Y.2    Yamamoto, M.3
  • 15
    • 0034111840 scopus 로고    scopus 로고
    • A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression
    • T. Suehiro, T. Nakamura, and M. Inoue A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression Atherosclerosis 150 2000 295 298
    • (2000) Atherosclerosis , vol.150 , pp. 295-298
    • Suehiro, T.1    Nakamura, T.2    Inoue, M.3
  • 16
    • 0033973018 scopus 로고    scopus 로고
    • Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
    • I. Leviev, and R.W. James Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations Arterioscler. Thromb. Vasc. Biol. 20 2000 516 521
    • (2000) Arterioscler. Thromb. Vasc. Biol. , vol.20 , pp. 516-521
    • Leviev, I.1    James, R.W.2
  • 18
    • 0031921406 scopus 로고    scopus 로고
    • Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus
    • Y. Ikeda, T. Suehiro, and M. Inoue Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus Metabolism 47 1998 598 602
    • (1998) Metabolism , vol.47 , pp. 598-602
    • Ikeda, Y.1    Suehiro, T.2    Inoue, M.3
  • 19
    • 0033756537 scopus 로고    scopus 로고
    • Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes
    • M. Inoue, T. Suehiro, and T. Nakamura Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes Metabolism 49 2000 1400 1405
    • (2000) Metabolism , vol.49 , pp. 1400-1405
    • Inoue, M.1    Suehiro, T.2    Nakamura, T.3
  • 20
    • 0032554676 scopus 로고    scopus 로고
    • Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
    • WOSCOP study group
    • WOSCOP study group Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) Circulation 97 1998 1440 1445
    • (1998) Circulation , vol.97 , pp. 1440-1445
  • 21
    • 0034053890 scopus 로고    scopus 로고
    • Non-lipid-related effects of statins
    • S. Bellosta, N. Ferri, and F. Bernini Non-lipid-related effects of statins Ann. Med. 32 2000 164 176
    • (2000) Ann. Med. , vol.32 , pp. 164-176
    • Bellosta, S.1    Ferri, N.2    Bernini, F.3
  • 22
    • 0027492038 scopus 로고
    • Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages
    • L.M. Giroux, J. Davignon, and M. Naruszewicz Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages Biochim. Biophys. Acta 1165 1993 335 338
    • (1993) Biochim. Biophys. Acta , vol.1165 , pp. 335-338
    • Giroux, L.M.1    Davignon, J.2    Naruszewicz, M.3
  • 23
    • 0032103277 scopus 로고    scopus 로고
    • Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
    • M. Aviram, M. Rosenblat, and C.L. Bisgaier Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation Atherosclerosis 138 1998 271 280
    • (1998) Atherosclerosis , vol.138 , pp. 271-280
    • Aviram, M.1    Rosenblat, M.2    Bisgaier, C.L.3
  • 24
    • 0033817620 scopus 로고    scopus 로고
    • Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients
    • M. Tomas, M. Senti, and F. Garcia-Faria Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients Arterioscler. Thromb. Vasc. Biol. 20 2000 2113 2119
    • (2000) Arterioscler. Thromb. Vasc. Biol. , vol.20 , pp. 2113-2119
    • Tomas, M.1    Senti, M.2    Garcia-Faria, F.3
  • 25
    • 0141456209 scopus 로고    scopus 로고
    • Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6
    • Y. Kumon, T. Suehiro, and Y. Ikeda Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6 Life Sci. 73 2003 2807 2815
    • (2003) Life Sci. , vol.73 , pp. 2807-2815
    • Kumon, Y.1    Suehiro, T.2    Ikeda, Y.3
  • 26
    • 0034534465 scopus 로고    scopus 로고
    • Heterogeneous Sp1 mRNAs in human HepG2 cells include a product of homotypic trans-splicing
    • T. Takahara, S.I. Kanazu, and S. Yanagisawa Heterogeneous Sp1 mRNAs in human HepG2 cells include a product of homotypic trans-splicing J. Biol. Chem. 275 2000 38067 38072
    • (2000) J. Biol. Chem. , vol.275 , pp. 38067-38072
    • Takahara, T.1    Kanazu, S.I.2    Yanagisawa, S.3
  • 27
    • 0034994075 scopus 로고    scopus 로고
    • Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I
    • G. Martin, H. Duez, and C. Blanquart Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I J. Clin. Invest. 107 2001 1423 1432
    • (2001) J. Clin. Invest. , vol.107 , pp. 1423-1432
    • Martin, G.1    Duez, H.2    Blanquart, C.3
  • 28
    • 0033618378 scopus 로고    scopus 로고
    • 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)
    • U. Laufs, D. Marra, and K. Node 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1) J. Biol. Chem. 274 1999 21926 21931
    • (1999) J. Biol. Chem. , vol.274 , pp. 21926-21931
    • Laufs, U.1    Marra, D.2    Node, K.3
  • 29
    • 0032487342 scopus 로고    scopus 로고
    • 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins
    • M. Essig, G. Nguyen, and D. Prie 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins Circ. Res. 83 1998 683 690
    • (1998) Circ. Res. , vol.83 , pp. 683-690
    • Essig, M.1    Nguyen, G.2    Prie, D.3
  • 30
    • 0026063559 scopus 로고
    • The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein
    • J.E. Buss, L.A. Quilliam, and K. Kato The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein Mol. Cell. Biol. 11 1991 1523 1530
    • (1991) Mol. Cell. Biol. , vol.11 , pp. 1523-1530
    • Buss, J.E.1    Quilliam, L.A.2    Kato, K.3
  • 32
    • 0035957682 scopus 로고    scopus 로고
    • Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect
    • L. Vincent, W. Chen, and L. Hong Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect FEBS Lett. 495 2001 159 166
    • (2001) FEBS Lett. , vol.495 , pp. 159-166
    • Vincent, L.1    Chen, W.2    Hong, L.3
  • 33
    • 0037155865 scopus 로고    scopus 로고
    • Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB
    • S.A. Holstein, C.L. Wohlford-Lenane, and R.J. Hohl Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB J. Biol. Chem. 277 2002 10678 10682
    • (2002) J. Biol. Chem. , vol.277 , pp. 10678-10682
    • Holstein, S.A.1    Wohlford-Lenane, C.L.2    Hohl, R.J.3
  • 34
    • 0037137175 scopus 로고    scopus 로고
    • Isoprenoids influence expression of Ras and Ras-related proteins
    • S.A. Holstein, C.L. Wohlford-Lenane, and R.J. Hohl Isoprenoids influence expression of Ras and Ras-related proteins Biochemistry 41 2002 13698 13704
    • (2002) Biochemistry , vol.41 , pp. 13698-13704
    • Holstein, S.A.1    Wohlford-Lenane, C.L.2    Hohl, R.J.3
  • 35
    • 0030749232 scopus 로고    scopus 로고
    • Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism
    • J.A. Cuthbert, and P.E. Lipsky Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism Cancer Res. 57 1997 3498 3505
    • (1997) Cancer Res. , vol.57 , pp. 3498-3505
    • Cuthbert, J.A.1    Lipsky, P.E.2
  • 36
    • 0242721909 scopus 로고    scopus 로고
    • Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: A role for sterol regulatory element-binding protein-2
    • S. Deakin, I. Leviev, and S. Guernier Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2 Arterioscler. Thromb. Vasc. Biol. 23 2003 2083 2089
    • (2003) Arterioscler. Thromb. Vasc. Biol. , vol.23 , pp. 2083-2089
    • Deakin, S.1    Leviev, I.2    Guernier, S.3
  • 37
    • 0032921557 scopus 로고    scopus 로고
    • Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants
    • M. Aviram, M. Rosenblat, and S. Billecke Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants Free Radic. Biol. Med. 26 1999 892 904
    • (1999) Free Radic. Biol. Med. , vol.26 , pp. 892-904
    • Aviram, M.1    Rosenblat, M.2    Billecke, S.3
  • 38
    • 0033002575 scopus 로고    scopus 로고
    • Simvastatin decreases aldehyde production derived from lipoprotein oxidation
    • J. Girona, A.E. La Ville, and R. Sola Simvastatin decreases aldehyde production derived from lipoprotein oxidation Am. J. Cardiol. 83 1999 846 851
    • (1999) Am. J. Cardiol. , vol.83 , pp. 846-851
    • Girona, J.1    La Ville, A.E.2    Sola, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.